Human monoclonal antibodies to ganglioside GD2
AssigneeBioNTech SE
InventorsWolfgang Scholz, Ritsuko Sawada
Life of this patent
Estimating the term…
Loading patent…
AssigneeBioNTech SE
InventorsWolfgang Scholz, Ritsuko Sawada
Estimating the term…
The present invention provides compositions for the production of an antibody or functional fragment thereof directed against disialoganglioside-GD2. The compositions of the invention include polynucleotides encoding a heavy chain and/or a light chain variable domain that binds to GD2. The invention also provides an isolated antibody or functional fragment thereof and methods of treating or preventing a disease, such as cancer or tumor formation, wherein the antibody or functional fragment includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. The invention further provides a conjugate of an antibody or functional fragment thereof conjugated or recombinantly fused to a diagnostic agent, detectable agent or therapeutic agent, and methods of treating, preventing or diagnosing a disease in a subject in need thereof.
An isolated antibody or antigen binding fragment thereof that binds to GD2, said antibody or antigen binding fragment thereof comprising a variable heavy chain (VH) domain and a variable light chain (VL) domain;
An isolated antibody or antigen binding fragment thereof that binds to GD2, said antibody or antigen binding fragment thereof comprising a variable heavy chain (VH) domain and a variable light chain (VL) domain, wherein said VH domain has the amino acid sequence of SEQ ID NO:
Dependencies are inferred from the claim text.